Research Article Details
| Article ID: | A27532 |
| PMID: | 18176372 |
| Source: | Gastroenterol Clin Biol |
| Title: | [Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome]. |
| Abstract: | Metabolic fatty liver diseases (Non Alcoholic Fatty Liver Diseases-NAFLD) are liver abnormalities (steatosis and steatohépatitis) commonly related to visceral obesity and to the metabolic syndrome. The pathogenesis of metabolic fatty liver diseases is most probably linked to the adipose tissue insulin resistance with a very high free fatty acids release, an abnormal secretion of factors produced by the adipose tissue (adipokines) and a low grade of chronic inflammation. The link between metabolic fatty liver diseases and the metabolic syndrome is further supported by epidemiological studies, as well as the frequently encountered cardio-vascular complications in both diseases. Changes in lifestyle with dietary restriction and increased physical activity are mandatory and similar for both conditions. Drugs such as thiazolidinediones, known to reduce insulin resistance and inflammation, still need further evaluation. |
| DOI: | 10.1016/s0399-8320(07)78350-1 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D366 | Thiazolidinediones | Chemical drug | DB11898 | -- | -- | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |